Effect of Latanoprost on Optic Nerve Perfusion
Optic Nerve Head Perfusion Following Treatment with Latanoprost 0.005% in Primary Open Angle Glaucoma: an Optical Coherence Tomography Angiography Study
1 other identifier
interventional
46
1 country
1
Brief Summary
46 eyes of 23 patients have been treated with topical Latanoprost 0.005 %. visual field was performed on all eyes. NFLT was measured using OCT. Radial peripapillary capillary (RPC) vascular density was measured using OCTA . mean ocular perfusion pressure (MOPP), and RPC vascular density were measured before and after treatment BY 2-3 MONTHS
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_1
Started Jun 2024
Shorter than P25 for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 24, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 30, 2024
CompletedFirst Submitted
Initial submission to the registry
September 28, 2024
CompletedFirst Posted
Study publicly available on registry
October 8, 2024
CompletedOctober 8, 2024
September 1, 2024
2 months
September 28, 2024
October 4, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
quantify the peri papillary capillary (microvasculature) density using OCTA
quantify the capillary (microvasculature) density in both the entire image and in the peripapillary region specifically the superior, nasal, inferior, and temporal quadrants
3 months
Study Arms (1)
EFFECT OF ANTI GLAUCOMA LATANOPROST 0.005 ON OPTIC NERVE PERFUSION
OTHEREFFECT OF ANTI GLAUCOMA PROSTAGLANDIN 0.005 ON OPTIC NERVE PERFUSION
Interventions
MEAN OCULAR PERFUSION PRESSURE WAS MEASURED AND CORRELATED TO THE IOP AND OPTIC NERVE PERFUSION IN RESPONSE TO LATANOPROST TREATMENT
Eligibility Criteria
You may qualify if:
- POAG with no past ocular surgery or laser retinal treatment. No previous anti-glaucoma medications
You may not qualify if:
- optic nerve lesions other than glaucoma
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Zagazig University
Zagazig, Sharqia Province, 44511, Egypt
Related Publications (2)
Harris A, Migliardi R, Rechtman E, Cole CN, Yee AB, Garzozi HJ. Comparative analysis of the effects of dorzolamide and latanoprost on ocular hemodynamics in normal tension glaucoma patients. Eur J Ophthalmol. 2003 Jan-Feb;13(1):24-31. doi: 10.1177/112067210301300104.
PMID: 12635671BACKGROUNDGherghel D, Hosking SL, Cunliffe IA, Armstrong RA. First-line therapy with latanoprost 0.005% results in improved ocular circulation in newly diagnosed primary open-angle glaucoma patients: a prospective, 6-month, open-label study. Eye (Lond). 2008 Mar;22(3):363-9. doi: 10.1038/sj.eye.6702639. Epub 2006 Nov 17.
PMID: 17115020BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 28, 2024
First Posted
October 8, 2024
Study Start
June 24, 2024
Primary Completion
August 30, 2024
Study Completion
August 30, 2024
Last Updated
October 8, 2024
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will not share